Alzheimer's drug memantine tested on healthy brains – but study halted early
NCT ID NCT02288000
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study aimed to see if taking memantine, an Alzheimer's drug, for 15 days would change certain brain and cognitive markers in healthy young men aged 18-30. The goal was to validate a test battery for future Alzheimer's drug development. However, the study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Memantine
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Lille/ Centre d'investigation Clinique
Lille, 59037, France
-
CIC Marseille
Marseille, France
-
CIC Toulouse
Toulouse, France